"Quinupramine"

[Antidepressant treatment by I.V. route compared to oral route of administration (author's transl)]. The therapeutic effects of oral and intravenous administration of a tricyclic antidepressant, Quinupramine, in depressive states, were compared in a double blind double placebo clinical study for an initial period of ten days. Treatment was continued by the oral route in an open study lasting one of activity following oral or parenteral administration was not observed in cases of neurotic or reactive depressions, where there was a good initial improvement, but this is not maintained clinically for long periods after perfusion therapy. Quinupramine injectable should be prescribed for the more severe cases of endogenous depressions as urgent therapy. The beneficial effects of the perfusions can

‡ * Protriptyline * Quinupramine‡ * Tianeptine * Trimipramine

‡ * Protriptyline * Quinupramine‡ * Tianeptine * Trimipramine

‡ * Protriptyline * Quinupramine‡ * Tianeptine * Trimipramine

, Elepsin) * Melitracen§ (Deanxit, Dixeran, Melixeran, Trausabun) * Metapramine† (Timaxel) * Nitroxazepine‡ (Sintamil) * Noxiptiline‡ (Agedal, Elronon, Nogedal) * Pipofezine‡ (Azafen/Azaphen) * Propizepine† (Depressin, Vagran) * Quinupramine† (Kevopril, Kinupril, Adeprim, Quinuprine)And the following are TCAs that act via main mechanisms other than serotonin or norepinephrine reuptake inhibition

), Anticholinesterase agents (Neostigmine methylsulfate, etc), Cholinergic agonists (Bethanechol Cl, etc), Benign prostatic hyperplasia agents (Tamsulosin HCl, Prazosin HCl, Terazosin HCl, Doxazosin mesylate, Silodosin, Naftopidil, etc), Tricyclic antidepressants (Amitriptyline, Clomipramine, Dosulepin, Doxepin, Imipramine, Quinupramine, etc), 6 months: 5-α-Reductase Inhibitors (Finasteride, Dutasteride) * Presence